New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Er...(ericans. GERD is often characterized by ...),Health

Date:10/26/2009

ericans. GERD is often characterized by frequent and persistent heartburn that occurs two or more days a week despite treatment and diet changes. GERD can affect both men and women, and symptoms are often triggered by certain foods, stress or pressure on the stomach. Up to 70 percent of GERD patients have non-erosive GERD, a term used to describe symptoms suggestive of GERD in patients with no endoscopic evidence of EE.

About KAPIDEX(TM) (dexlansoprazole) delayed release capsules

KAPIDEX (dexlansoprazole) delayed release capsules is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. KAPIDEX, taken once daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

KAPIDEX is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with KAPIDEX use. Symptomatic response with KAPIDEX does not preclude the presence of gastric malignancy. The most commonly reported treatment-emergent adverse reactions (greater than or equal to 2%) include diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). KAPIDEX must not be co-administered with atazanavir because atazanavir systemic concentrations may be substantially decreased. KAPIDEX may interfere with the absorption of drugs for which gastric pH is important for b
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. New Study Confirms VASER Lipo Results Are Superior to Standard Liposuction
2. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
3. Delcath Systems, Inc. Completes Phase III Study Enrollment
4. AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed
5. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
6. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
7. comScore Study Finds the Internet a Key Component in Consumer Research on Prescriptions and Health Conditions
8. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
9. CVS Caremark Undertakes Multi-Year Study to Improve Patient Medication Adherence
10. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
11. DATATRAK Signs 6 Year Study with New Device Client